Show simple item record

dc.contributor.authorAlhalabi, K. T.
dc.contributor.authorStichel, D.
dc.contributor.authorSievers, P.
dc.contributor.authorPeterziel, H.
dc.contributor.authorSommerkamp, A. C.
dc.contributor.authorSturm, D.
dc.contributor.authorWittmann, A.
dc.contributor.authorSill, M.
dc.contributor.authorJäger, N.
dc.contributor.authorBeck, P.
dc.contributor.authorPajtler, K. W.
dc.contributor.authorSnuderl, M.
dc.contributor.authorJour, G.
dc.contributor.authorDelorenzo, M.
dc.contributor.authorMartin, A. M.
dc.contributor.authorLevy, A.
dc.contributor.authorDalvi, N.
dc.contributor.authorHansford, J. R.
dc.contributor.authorGottardo, N. G.
dc.contributor.authorUro-Coste, E.
dc.contributor.authorMaurage, C. A.
dc.contributor.authorGodfraind, C.
dc.contributor.authorVandenbos, F.
dc.contributor.authorPietsch, T.
dc.contributor.authorKramm, C.
dc.contributor.authorFilippidou, M.
dc.contributor.authorKattamis, A.
dc.contributor.authorJones, C.
dc.contributor.authorØra, I.
dc.contributor.authorMikkelsen, T. S.
dc.contributor.authorZapotocky, M.
dc.contributor.authorSumerauer, D.
dc.contributor.authorScheie, D.
dc.contributor.authorMcCabe, Martin G
dc.contributor.authorWesseling, P.
dc.contributor.authorTops, B. B. J.
dc.contributor.authorKranendonk, M. E. G.
dc.contributor.authorKarajannis, M. A.
dc.contributor.authorBouvier, N.
dc.contributor.authorPapaemmanuil, E.
dc.contributor.authorDohmen, H.
dc.contributor.authorAcker, T.
dc.contributor.authorvon Hoff, K.
dc.contributor.authorSchmid, S.
dc.contributor.authorMiele, E.
dc.contributor.authorFilipski, K.
dc.contributor.authorKitanovski, L.
dc.contributor.authorKrskova, L.
dc.contributor.authorGojo, J.
dc.contributor.authorHaberler, C.
dc.contributor.authorAlvaro, F.
dc.contributor.authorEcker, J.
dc.contributor.authorSelt, F.
dc.contributor.authorMilde, T.
dc.contributor.authorWitt, O.
dc.contributor.authorOehme, I.
dc.contributor.authorKool, M.
dc.contributor.authorvon Deimling, A.
dc.contributor.authorKorshunov, A.
dc.contributor.authorPfister, S. M.
dc.contributor.authorSahm, F
dc.contributor.authorJones, D. T. W.
dc.date.accessioned2021-09-07T13:16:23Z
dc.date.available2021-09-07T13:16:23Z
dc.date.issued2021en
dc.identifier.citationAlhalabi KT, Stichel D, Sievers P, Peterziel H, Sommerkamp AC, Sturm D, et al. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathol. 2021 Aug 21.en
dc.identifier.pmid34417833en
dc.identifier.doi10.1007/s00401-021-02354-8en
dc.identifier.urihttp://hdl.handle.net/10541/624564
dc.description.abstractLarge-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00401-021-02354-8en
dc.titlePATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrumen
dc.typeArticleen
dc.contributor.departmentHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germanyen
dc.identifier.journalActa Neuropathologicaen
dc.description.noteen]
refterms.dateFOA2021-09-08T13:12:28Z


Files in this item

Thumbnail
Name:
34417833.pdf
Size:
3.493Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record